OKYO OKYO Pharma Limited
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical tria…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Sector Update: Healthcare Stocks Rise Late Afternoon Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the | ||
Sector Update: Healthcare Stocks Advance Tuesday Afternoon Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.4% and the | ||
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key Earnings Reports The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5%, and the actively tra | ||
 OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report for the fiscal year ended March 31, 2026, outlining its financial position and progress toward a planned Phase 3 clinical trial for its lead drug candidate. The clinical-stage biopharmaceutical company said... | ||
 OKYO Pharma advances toward Phase 3 FDA trial - ICYMI OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting with the US Food and Drug Administration (FDA), providing greater regulatory clarity as the company advances urcosimod toward a global Phase 3 pivotal study for neuropathic corneal pain... | ||
 OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from a US Food and Drug Administration Type D meeting that supports advancing its investigational therapy urcosimod into a global Phase 3 pivotal trial for neuropathic corneal pain (NCP). The clinical-stage... | ||
 OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain OKYO Pharma’s CEO Robert Dempsey joined Steve Darling from Proactive to discuss positive feedback received from a U.S. Food and Drug Administration (FDA) Type D meeting, providing greater clarity on the regulatory pathway for urcosimod and supporting the company’s plans to advance the therapy into a global Phase 3 pivotal trial for neuropathic corneal pain (NCP). Dempsey said the FDA’s guidance validated the company’s updated regulatory strategy and reduced uncertainty surrounding the clinical development program. Based on discussions with the agency, OKYO is positioning its planned NEPTUNE Phase 3 trial as a pivotal study that could potentially support a single-trial registration strategy, subject to positive clinical results and continued FDA review. Urcosimod is the first investigational therapy with an active Investigational New Drug (IND) application specifically targeting neuropathic corneal pain and has received FDA Fast Track designation, recognizing the significant unmet medical need for a condition that currently has no approved treatments. Neuropathic corneal pain is a chronic and often debilitating disease characterized by severe eye pain and heightened sensitivity that can extend to the face and head. The condition is believed to result from damage or dysfunction of the corneal sensory nerves, often accompanied by inflammation, and patients frequently experience pain that is disproportionate to observable clinical findings. Dempsey said the positive FDA feedback strengthens the company’s confidence in its development plan and represents an important milestone as OKYO works to bring what could become the first approved therapy for neuropathic corneal pain to patients. #proactiveinvestors #okyopharmalimited #nasdaq #okyo #Urcosimod #NeuropathicCornealPain #HealthcareInnovation #ClinicalDevelopment #NeuroInflammation #CornealDisease #Pharmaceuticals #MedTech #DrugDevelopment #MartaSacchetti | ||